A neurologist-focused view of how blood-based biomarkers are changing referrals, why amyloid confirmation remains unsettled, where payer and monitoring requirements slow treatment, how ApoE and ARIA shape risk decisions, and what early Alzheimer’s care may need next.
Audience: Neurologists
Countries: 6
Completion Rate: 70.9%
SGID: 8944880
-Hero findings
– Quick Read — Key Findings
Blood-based biomarkers and anti-amyloid therapies have changed what a positive Alzheimer’s signal can mean in neurology. The clinical question is no longer only whether amyloid pathology is present. It is whether the patient is at the right disease stage, whether the result is sufficiently reliable for the intended use, whether amyloid confirmation is needed, whether genetic and MRI risk can be managed, and whether the health system can actually deliver treatment.
External guidance is moving fast: in 2025 the Alzheimer’s Association issued its first evidence-based guideline for blood-based biomarkers in specialty care, using performance thresholds rather than endorsing one product and separating triage tests from those accurate enough to substitute for PET or CSF; the FDA cleared the first Alzheimer’s blood test in May 2025, with more p-tau217 tests entering the pathway by August 2026, all meant to aid diagnosis in people with cognitive impairment, not to screen asymptomatic adults. Treatment adds another layer, FDA labeling places lecanemab and donanemab in MCI or mild dementia with confirmed amyloid, requires MRI monitoring for ARIA and ApoE ε4 testing beforehand, and U.S. Medicare coverage runs through registries, so diagnostic innovation can bring more patients to neurology before access, safety, and workflow capacity are equally ready.
31.0% say they receive referrals from primary care after a positive blood test a few times a quarter.
Beyond the 31.0% seeing referrals a few times a quarter, 26.2% say primary care in their network does not order these tests, while 21.4% receive them frequently and 21.4% rarely, a spread that marks a transition rather than a settled pathway. Because FDA-cleared tests are meant for symptomatic patients and must be read with clinical context, referral growth stays manageable only if a positive result arrives with enough information to sort who needs confirmation, who needs a specialist visit first, and who should not be routed straight into a treatment discussion.
35.7% require CSF analysis before considering a disease-modifying therapy, while 26.2% say a validated high-accuracy blood biomarker plus clinical MRI is sufficient.
Amyloid PET is required by 19.0% and another 19.0% require both PET and CSF for certainty, and confirmation is exactly where new guidance could change practice fastest. The 2025 Alzheimer’s Association guideline is performance-based, a sensitive triage test can flag who needs confirmatory PET or CSF, while a test meeting higher thresholds may substitute in an appropriate specialty workup, but that does not make every assay equivalent or remove the need to weigh the patient’s syndrome, stage, MRI, and treatment goals.
57.1% identify payer friction, prior authorization delays, and Medicare or insurance hurdles as the single greatest operational bottleneck.
Payer friction dominates at 57.1%, with rapid MRI access (16.7%), neurologist workforce and shared-decision time (14.3%), and infusion capacity (11.9%) trailing, so the delivery challenge runs well beyond drug supply, each candidate can need amyloid confirmation, genetic counseling, baseline and follow-up MRI, infusion logistics, coverage steps, and repeated family conversations. With U.S. CMS coverage carrying registry requirements and the survey spanning six countries, the message holds broadly: financial authorization becomes a clinical workflow problem the moment it delays confirmation, initiation, or follow-up.
73.2% would pause dosing, monitor with serial MRI until resolution, and cautiously re-challenge after asymptomatic low-grade ARIA-E.
Alongside the imaging response, 61.0% consider ApoE testing strictly mandatory before prescribing, 26.8% highly recommend it, 4.9% reserve it for selected cases, and 7.3% do not routinely order it, consistent with FDA labels calling for ApoE ε4 testing and counseling before treatment. Because current U.S. labels allow continued dosing for asymptomatic mild ARIA-E while reserving interruption for greater severity or symptoms, the strong preference for pausing signals a conservative real-world posture even when the event is low-grade.
56.1% believe the most profound clinical benefit will be seen in mild cognitive impairment, while 36.6% would stop DMT after plaque clearance but continue serial blood-biomarker monitoring.
The concentration on MCI at 56.1%, with pre-clinical, subjective cognitive decline, and early symptomatic disease each at 14.6%, reflects where current therapies are initiated, though the open-ended comments show stage alone is not enough given uncertainty about prognosis, burden, comorbidities, access, and ARIA risk. The longitudinal question is less settled: after plaque clearance, 36.6% would stop but monitor with serial blood biomarkers and retreat if levels rise, 34.1% are unsure given thin data, 17.1% prefer lower-dose maintenance, and 12.2% would stop and monitor clinically, making the end of the initial course a new decision point rather than a finish line.
35.0% expect a strict specialist triage model if annual blood-biomarker screening ever becomes standard in primary care, and 42.5% prioritize next-generation DMTs with substantially lower ARIA risk.
The primary-care screening scenario is hypothetical, since cleared tests aid diagnosis in symptomatic patients rather than screen asymptomatic adults, but it exposes the capacity question: 35.0% expect strict triage, 30.0% positive transformation, 27.5% backlog and false-positive pressure, and 7.5% minimal impact. On the future of treatment, improved safety leads at 42.5%, blood biomarkers replacing PET and CSF at 35.0%, at-home subcutaneous formulations at 20.0%, and AI-assisted ARIA grading at 2.5%, while sentiment stays measured (52.5% cautiously optimistic, 25.0% enthusiastic, 20.0% skeptical, 2.5% unsupportive), suggesting neurologists want a safer, more scalable model before a larger diagnostic funnel arrives.
The survey shows a neurology pathway in active transition. Blood biomarkers are starting to change referrals, yet the largest group sees them only occasionally and more than a quarter report that primary care does not order them, and when a positive result arrives, confirmatory practice stays split between CSF, PET, combined confirmation, and high-accuracy blood testing plus MRI.
The harder friction appears once diagnostic possibility becomes treatment intent: payer and authorization hurdles dominate, while ApoE counseling and MRI-based ARIA management add safety work inseparable from prescribing. MCI is the clearest treatment window, but the open-ended responses show how hard the individual decision is when symptoms are limited, benefit is modest, and treatment burden or ARIA risk is meaningful.
The next phase of early Alzheimer’s care will depend on more than better biomarkers. Neurologists need referral rules, confirmation thresholds, coverage pathways, MRI access, longitudinal monitoring, and communication models that scale together. The prevailing sentiment is cautiously optimistic, which may describe the field itself: a meaningful therapeutic shift with the operational model still catching up.
You have read the summary
Common questions about blood testing, amyloid confirmation, ApoE, ARIA, treatment eligibility, and early Alzheimer’s disease-modifying therapy.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
